In Reply We thank Bhatt et al for their comments. They are concerned about the reduced cycle of adjuvant chemotherapy in primary cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC). In the total study group and each subgroup, the number of chemotherapy and completeness of 6 cycles were not statistically different according to HIPEC. In the primary cytoreductive surgery subgroup, the number of adjuvant chemotherapy less than 6 cycles was 6.1% in the control group and 6.9% in the HIPEC group (P > .99). In the interval cytoreductive surgery after neoadjuvant chemotherapy subgroup, the number of adjuvant chemotherapy less than 6 cycles was 20.9% in the control group and 20.6% in the HIPEC group (P = .97). In the HIPEC group, the number of adjuvant chemotherapy less than 6 cycles was 6.9% in the primary cytoreductive group and 20.6% in the interval cytoreductive group after neoadjuvant chemotherapy (P = .09).
Lim MC, Park B, Park S. Perspectives on Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian Cancer—Reply. JAMA Surg. 2022;157(10):970–971. doi:10.1001/jamasurg.2022.2941
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.